MYRIAD GENETICS INC (MYGN)

US62855J1043 - Common Stock

13.5  -0.24 (-1.75%)

After market: 13.5 0 (0%)

MYRIAD GENETICS INC

NASDAQ:MYGN (12/26/2024, 8:00:01 PM)

After market: 13.5 0 (0%)

13.5

-0.24 (-1.75%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%300%
Sales Q2Q%11.15%
CRS6.88
6 Month-44.81%
Overview
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Ins Owners2.22%
Inst Owners104.29%
Market Cap1.23B
Shares91.04M
PE96.43
Fwd PE130.87
Dividend YieldN/A
Analysts71.43
Short Float %3.81%
Short Ratio3.7
IPO10-06 1995-10-06
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

MYGN Daily chart

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

Company Info

MYRIAD GENETICS INC

322 North 2200 West

Salt Lake City UTAH 84108

P: 18015843600

CEO: R. Bryan Riggsbee

Employees: 2700

Website: https://myriad.com/

MYGN News

News Image7 days ago - Myriad Genetics, Inc.Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model

News Image7 days ago - Myriad Genetics, Inc.Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine....

News Image16 days ago - Myriad Genetics, Inc.Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
News Image16 days ago - Myriad Genetics, Inc.Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

Myriad Genetics provides update on discussions with UnitedHealthcare regarding medical policy for pharmacogenetic testing....

News Image16 days ago - Myriad Genetics, Inc.Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
News Image16 days ago - Myriad Genetics, Inc.Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members....

MYGN Twits

Here you can normally see the latest stock twits on MYGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example